News & Events zu ITG, Inc. Class A Common Stock (ITG)ITGITG, Inc. Class A Common Stock

Company Reports Q2 Revenue of $404.6M

Reports Q2 revenue $404.6M, consensus $385.10M. Performance was driven by contributions from recent acquisitions, expansion of existing and new customer programs, and increased activity under recently awarded contracts. "Our second quarter results reflect continued momentum across the business and strong execution of our growth strategy," said CEO Andy Parrott.

Scribe Therapeutics Debuts Above Issue Price on First Trading Day

Scribe Therapeutics makes its public debut above issue price as the CRISPR drug developer opened for trading last week. The biotech entered the market with cardiometabolic programs at the forefront and early momentum behind its platform story.LATEST IPOS AND DIRECT LISTINGS:Scribe Therapeuticsopened on July 24 at $25. Scribe, which priced 8.58M shares at $15.00, describes itself as a clinical-stage biotechnology company engineering CRISPR-based technologies into "purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases," starting with cardiometabolic disease.RECENT SPAC IPOS:Market Technology Acquisitionopened on July 24 at $10.00. The company's primary focus is businesses operating "across the global capital markets ecosystem, with particular emphasis on licensed U.S. equities and options clearing businesses and related market infrastructure, and post-trade, brokerage, custody, execution and financial technology platforms."B&R Technology Mergeropened on July 21 at $9.96. The company may pursue an initial business combination target in any business or industry. Citigroup is acting as sole bookrunner and representative of the underwriters.Southern Cross Acquisition Iopened on July 21 at $10. D. Boral Capital is acting as sole book-running manager of the offering.PERFORMANCE:Prices as of 11 am ET on Monday, July 27 -Scribe Therapeutics – down about 13% at $18.86.RECENT IPOS TO WATCH:Bending Spoons, Neutron Holdingsand ITG, Inc.are already seeing coverage roll out as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include EvoAir, Jersey Mike's Subs, Reformation, Braveheart Bio, and Inspire Brands.Clickto see upcoming IPO calendar on TipRanks.EvoAir Holdingshas filed for a firm commitment initial public offering of shares of common stock and anticipates that the initial public offering price of shares will be between $4.00 and $5.00 per share. The company said it will apply to list its common stock on the Nasdaq Capital Market under the symbol "EVOH". EvoAir Group is an emerging green technology focusing on eco-friendly heating, ventilation, air conditioning inventions and efforts in the environmental, social and governance initiatives. The Group is principally engaged in the research and development, manufacturing, sale and marketing of HVAC products for residential, commercial and industrial uses.Jersey Mike's Subsannounced that it has commenced a roadshow for its proposed initial public offering of 43,478,261 shares of its Class A common stock to be sold by Jersey Mike's and certain of its existing stockholders. The IPO price is currently expected to be between $21.00 and $25.00 per share. In addition, the Selling Stockholders are expected to grant the underwriters a 30-day option to purchase up to an additional 6,521,739 shares of the Company's Class A common stock to cover over-allotments at the IPO price, less underwriting discounts and commissions. Jersey Mike's expects to list its Class A common stock on the New York Stock Exchange under the ticker symbol "JMKE."Reformationannounced the launch of its roadshow for the initial public offering of 14,062,500 shares of its common stock. Reformation is offering 9,478,821 shares of common stock and certain of its existing stockholders are offering 4,583,679 shares of common stock. In connection with the offering, the Selling Stockholders are expected to grant the underwriters a 30-day option to purchase up to an additional 2,109,375 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is expected to be between $15.00 and $17.00 per share. Reformation has been approved to list its common stock on the New York Stock Exchange under the ticker symbol "REF."Braveheart Biohas filed with the SEC for an initial public offering of shares of its common stock and applied to list its common stock on The Nasdaq Global Market under the symbol "BRVE". Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor are listed as the joint bookrunners. The prospectus states, "We are a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor, that we are developing for the treatment of obstructive HCM and non-obstructive HCM."Inspire Brandsannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.